Zone7

Company Overview

Snapshot

Founded in February 2017 by Tal Brown and Eyal Eliakim, Zone7 operates with 11–50 employees. The company has raised $10.5 million across 2 funding rounds from 9 investors. In July 2021, Zone7 secured its Series A round, led by Blumberg Capital.

Business overview

Zone7, also known as InPlay, develops an AI-powered platform for injury prediction and performance optimization in athletes. The company's core technology creates personalized athlete profiles by analyzing data from wearable devices, medical records, and other physiological and screening products. This enables Zone7 to predict injury risks and recommend optimal training drills and performance levels, serving the digital health, sports tech, and artificial intelligence sectors.

Strategic signal

In February 2025, co-founder and CTO Eyal Eliakim joined Team8, signaling a potential leadership transition or strategic evolution for Zone7. This move suggests a shift in key personnel that could influence the company's future technological direction and strategic partnerships within the broader tech and venture ecosystem.

Company Intelligence Q&A

What is Zone7's primary focus?

Zone7 specializes in an AI-powered injury prediction and performance optimization solution designed for athletes. The platform uses data from various sources to create personalized profiles and recommend training adjustments.

When was Zone7 founded and by whom?

Zone7 was founded in February 2017 by Tal Brown and Eyal Eliakim.

What was a significant funding event for Zone7?

In July 2021, Zone7 raised its Series A funding round, with Blumberg Capital leading the investment.

What is the total capital raised by Zone7?

Zone7 has raised a total of $10.5 million across two funding rounds.

What was a notable leadership change at Zone7?

In February 2025, Eyal Eliakim, co-founder and CTO of Zone7, joined Team8.